PMGC (ELAB) Competitors $1.99 -0.04 (-1.97%) Closing price 04:00 PM EasternExtended Trading$1.96 -0.03 (-1.46%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ELAB vs. BCDA, PHXM, PCSA, CLDI, INAB, SNSE, SONN, CARM, NLSP, and HOOKShould you be buying PMGC stock or one of its competitors? The main competitors of PMGC include BioCardia (BCDA), PHAXIAM Therapeutics (PHXM), Heatwurx (PCSA), Calidi Biotherapeutics (CLDI), IN8bio (INAB), Sensei Biotherapeutics (SNSE), Sonnet BioTherapeutics (SONN), Carisma Therapeutics (CARM), NLS Pharmaceutics (NLSP), and HOOKIPA Pharma (HOOK). These companies are all part of the "pharmaceutical products" industry. PMGC vs. Its Competitors BioCardia PHAXIAM Therapeutics Heatwurx Calidi Biotherapeutics IN8bio Sensei Biotherapeutics Sonnet BioTherapeutics Carisma Therapeutics NLS Pharmaceutics HOOKIPA Pharma BioCardia (NASDAQ:BCDA) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Which has stronger earnings & valuation, BCDA or ELAB? PMGC has lower revenue, but higher earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$60K187.53-$7.95M-$1.85-1.05PMGCN/AN/A-$6.25M-$433.870.00 Is BCDA or ELAB more profitable? PMGC's return on equity of -62.73% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets BioCardiaN/A -19,117.42% -246.92% PMGC N/A -62.73%-52.83% Which has more risk and volatility, BCDA or ELAB? BioCardia has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, PMGC has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Does the media favor BCDA or ELAB? In the previous week, PMGC had 7 more articles in the media than BioCardia. MarketBeat recorded 9 mentions for PMGC and 2 mentions for BioCardia. BioCardia's average media sentiment score of 1.44 beat PMGC's score of 0.42 indicating that BioCardia is being referred to more favorably in the media. Company Overall Sentiment BioCardia Positive PMGC Neutral Do analysts prefer BCDA or ELAB? BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 1,188.66%. Given BioCardia's stronger consensus rating and higher probable upside, equities analysts plainly believe BioCardia is more favorable than PMGC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50PMGC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of BCDA or ELAB? 20.6% of BioCardia shares are held by institutional investors. Comparatively, 22.2% of PMGC shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 0.6% of PMGC shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryBioCardia beats PMGC on 9 of the 15 factors compared between the two stocks. Get PMGC News Delivered to You Automatically Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELAB vs. The Competition Export to ExcelMetricPMGCDIVERSIFIED OPS IndustryMulti-Sector SectorNASDAQ ExchangeMarket Cap$2.96M$16.17B$14.84B$9.78BDividend YieldN/A4.03%3.82%4.04%P/E Ratio0.0012.5710.3626.39Price / SalesN/A6.725.5386.63Price / CashN/A39.0737.0159.11Price / Book0.3319.7616.816.62Net Income-$6.25M$951.86M$922.56M$265.42M7 Day Performance4.74%5.75%4.56%3.58%1 Month Performance-12.72%0.65%0.09%0.46%1 Year Performance-99.56%-1.50%-2.57%19.41% PMGC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELABPMGC0.7132 of 5 stars$1.99-2.0%N/A-99.5%$2.96MN/A0.0018Gap DownBCDABioCardia3.8553 of 5 stars$1.88-0.3%$25.00+1,233.3%-29.2%$10.88M$60K-1.0140Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049PCSAHeatwurx3.347 of 5 stars$0.21-3.3%$2.00+852.4%-84.6%$10.57MN/A-0.0920Positive NewsCLDICalidi Biotherapeutics1.2755 of 5 stars$3.41-17.0%N/A-87.2%$10.55MN/A0.0038Insider TradeGap UpINABIN8bio3.7076 of 5 stars$2.27-5.0%$180.00+7,829.5%-85.3%$10.31MN/A-0.2520Positive NewsSNSESensei Biotherapeutics4.6884 of 5 stars$8.11-2.0%$55.00+578.6%-35.6%$10.21MN/A-0.3840Positive NewsGap DownSONNSonnet BioTherapeutics3.239 of 5 stars$3.21-4.3%$20.00+524.0%-41.4%$10.16M$20K0.0010Gap UpCARMCarisma Therapeutics2.996 of 5 stars$0.24-13.3%$1.93+695.5%-80.8%$10.11M$19.63M-0.1620NLSPNLS PharmaceuticsN/A$2.77+7.2%N/A+1,106.3%$9.95MN/A0.006Gap UpHOOKHOOKIPA Pharma2.868 of 5 stars$0.82-3.8%$4.50+451.8%-83.8%$9.94M$9.35M-0.14160Gap Up Related Companies and Tools Related Companies BCDA Alternatives PHXM Alternatives PCSA Alternatives CLDI Alternatives INAB Alternatives SNSE Alternatives SONN Alternatives CARM Alternatives NLSP Alternatives HOOK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELAB) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMGC Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMGC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access